Tag: greenmarketreport.com

  • One of Las Vegas’ cannabis lounges closes its doors

    One of Las Vegas’ cannabis lounges closes its doors

    Nevada’s cannabis lounge experiment faces some expected growing pains, with one of just two state-licensed venues closing its doors after barely a year in business, according to the Las Vegas Weekly.

    “The regulatory framework, compliance costs and product limitations just don’t support a sustainable business model,” said Thrive Cannabis managing partner Mitch Britten, who plans to convert the space into an event venue until regulations loosen up.

    The closure leaves Planet 13’s Dazed Consumption Lounge as the only operational state-regulated cannabis lounge in Nevada. Dazed manager Blake Anderson estimates the venue attracts around 250 customers daily, primarily tourists. One other establishment, Sky High Lounge, has operated since 2019 on sovereign Las Vegas Paiute Tribe land exempt from state regulations.

    Even with Nevada regulators conditionally approving 21 more lounge licenses, potential owners are struggling to meet the $200,000 liquid assets requirement – particularly social equity applicants from communities hit hardest by prohibition.

    Recreational marijuana has been legal statewide since 2017, but public consumption remains prohibited. That’s created an obvious disconnect for the millions of tourists who visit Las Vegas annually but have nowhere legal to use the products they purchase. The state recorded roughly $829 million in taxable sales during the 2024 fiscal year.

    “It always comes down to money, and it’s difficult to get a space if you can’t afford to buy a building. On top of that, getting insurance and finding a landowner who’s willing to lease to a cannabis business is a challenge in and of itself,” said Christopher LaPorte, whose consulting firm Reset Las Vegas helped launch Smoke and Mirrors, told Las Vegas Weekly.

    Many think the key to future success lies in legislative changes that would allow lounges to integrate with food service and entertainment – playing to Las Vegas’s strengths as a hospitality innovator. In the meantime, the industry will continue to adapt and push forward.

    “Things take time,” LaPorte said. “There’s a culture that we have to continue to embrace and a lot of education that we still have to do. But at the end of the day, tourists need a place to smoke, and that’s what these places are.”

    The post One of Las Vegas’ cannabis lounges closes its doors appeared first on Green Market Report.

  • Psyence Group consolidates its shares

    Psyence Group Inc. (CSE: PSYG) told investors that it will be consolidating all of its issued and outstanding share capital on the basis of every 15 existing common shares into one new common share effective April 23, 2025 with a record date of April 23, 2025. As a result of the consolidation, the issued and outstanding shares will be reduced to approximately 9,387,695 on the effective date.

    This is the second time a Psyence company has consolidated shares recently. In November, its Nasdaq-listed associate, Psyence Biomedical Ltd. (Nasdaq: PBM), implemented a 1-for-75 share consolidation as the psychedelics company worked to maintain its Nasdaq listing.

    Psyence Group reported earnings in February when the company delivered a net loss of C$3 million and was reporting as a going concern. At the end of 2024, the company said it had not yet achieved profitable operations, has accumulated losses of C$48,982,320 since its inception.

    Total assets at the end of 2024 were C$11,944,478 and comprised predominantly of: cash and cash equivalents of C$10,611,113, other receivables of C$159,808, investment in PsyLabs of C$1,071,981 and prepaids of C$68,243.

    Still, the company is pushing ahead. Psyence told investors that it has historically secured financing through share issuances and convertible debentures, and it continues to explore funding opportunities to support its operations and strategic initiatives. “Based on these actions and
    management’s expectations regarding future funding and operational developments, the company believes it will have sufficient resources to meet its obligations as they become due for at least the next twelve months,” it said in its last financial filing.

    The company said it believes that the consolidation will position it with greater flexibility for the development of its business and the growth of the company.

     

    The post Psyence Group consolidates its shares appeared first on Green Market Report.

  • Nebraska medical cannabis regulations stall in legislative committee

    Nebraska medical cannabis regulations stall in legislative committee

    A Nebraska legislative committee voted 5-3 against advancing a bill designed to implement and regulate the state’s medical cannabis program, leaving legislators and advocates searching for alternative paths forward, according to the Nebraska Examiner.

    The General Affairs Committee rejected Legislative Bill 677, sponsored by State Sen. Ben Hansen of Blair, during a Thursday vote where committee members declined to offer amendments to the legislation, the publication reported.

    “I don’t want to shut all the doors right now, but some doors are closing, and they’re closing fast, and so we have to act,” Hansen told reporters after the vote, according to the Examiner.

    Nebraska voters approved medical cannabis in November 2024, with residents legally permitted to possess up to 5 ounces with a healthcare practitioner’s recommendation since mid-December. However, the regulatory commission created by the ballot initiative lacks effective power and funding to regulate the industry.

    Hansen described his legislation as “a must” for 2025 to prevent a “Wild West” scenario in the state’s cannabis market. The bill would have expanded regulatory structure through the Nebraska Medical Cannabis Commission and extended deadlines for regulations and licensing to allow more time for implementation, the Examiner noted.

    Committee disagreements centered on proposed restrictions. A committee amendment would have prohibited smoking cannabis and the sale of flower or bud products while limiting qualified healthcare practitioners to physicians, osteopathic physicians, physician assistants or nurse practitioners who had treated patients for at least six months.

    The amendment also would have limited qualifying conditions to 15 specific ailments including cancer, epilepsy, HIV/AIDS, and chronic pain lasting longer than six months.

    State Sen. Bob Andersen of Sarpy County opposed allowing vaping due to concerns about youth drug use, while committee chair Rick Holdcroft suggested selling cannabis flower would be “a gateway toward recreational marijuana,” a claim Hansen “heavily disputed,” according to the Examiner.

    Hansen now faces a difficult path forward, requiring at least 25 votes to pull the bill from committee and then needing 33 senators to advance it across three rounds of debate, regardless of filibuster attempts.

    Crista Eggers, executive director of Nebraskans for Medical Marijuana, remained optimistic despite the setback.

    “This will not be the end,” Eggers said, according to the outlet. “Giving up has never been an option. Being silenced has never been an option. It’s not over. It’s not done.”

    The legislative impasse is further complicated by ongoing litigation. Former state senator John Kuehn has filed two lawsuits challenging the voter-approved provisions, with one appeal pending before the Nebraska Supreme Court. The state’s Attorney General is also trying to do something about the hemp question, akin to other states across the country.

    The post Nebraska medical cannabis regulations stall in legislative committee appeared first on Green Market Report.

  • Regulatory chaos threatens US hemp industry

    Regulatory chaos threatens US hemp industry

    The U.S. hemp-derived cannabinoid market has swelled in total value, but the industry continues to face serious threats from a messy patchwork of state bans and regulations that are stunting growth and pushing production overseas, according to a leading cannabis economist.

    “All this hysteria over cannabinoids is having a profound effect on the fiber and grain environment,” said Beau Whitney, founder of Whitney Economics, told Green Market Report in an interview.

    Whitney’s analysis shows the hemp market, including CBD, THC, CBN, CBG and related compounds, has grown into a robust industry that now rivals legal marijuana markets. Two years ago, his firm calculated the total market for hemp-derived cannabinoids ranged from $21.3 billion to $35.8 billion, with a midpoint of $28.4 billion.

    Of that total market, Whitney noted that “about $21 billion was available on the legal side and then about $7 billion was on the illicit side.”

    Recent surveys conducted by Whitney in states, including Arizona, Illinois, Tennessee and Texas, validated these projections. “In states where I could get data and states that allowed for the sales, that’s where (the data is) really solid,” Whitney said. “They’re being confirmed as being conservative.”

    While it isn’t an apples-to-apples comparison, since Whitney’s measuring total market potential for hemp against only legal sales in the marijuana world, the economist said it’s becoming nearly impossible to measure legal hemp sales accurately as state regulations constantly shift.

    “Every time I turn around, a different state has a different proposal to ban all of this,” Whitney said.

    As a result, Whitney’s firm focuses on measuring total market potential rather than solely legal sales. Still, he sees potential growth beyond current projections, especially with hemp-derived cannabis beverages making a splashy entrance to the market.

    “Hemp-derived cannabis beverages, Delta-9 beverages, are coming on in a big way,” he said, noting these products are breaking out of traditional CBD shops and into “bars, liquor stores, restaurants and grocery stores.”

    According to Whitney, legislative approaches to hemp cannabinoids have had unintended consequences across the broader hemp industry. The confusion also affects hemp fiber and grain sectors that have nothing to do with intoxicating products.

    “Banks are debanking hemp fiber and hemp grain companies,” Whitney claimed. “Investors are pulling back on investment into the infrastructure.”

    Whitney calculated that “the lost economic potential because of these legislatures was between $20 (billion) and $25 billion dollars.” He added that he’s “taken (his) acreage forecast through 2030 down by over 4 million acres.”

    Whitney estimated “an impact to farmers of between $1 (billion) and $3.5 billion in revenue” in lost opportunities.

    Licensed hemp acreage plummeted from 525,000 acres in 2019 to just 30,000 acres last year. That decline means there isn’t enough domestic acreage to support the hemp cannabinoid industry, potentially pushing manufacturing overseas.

    “It’s driving manufacturers to China and to South America and Canada and anywhere else that can get CBD or CBD biomass,” Whitney said, which creates additional public safety risks as “Chinese CBD is laden with heavy metals.”

    He said that the irony is that policies ostensibly designed to protect public safety might actually be increasing risks. “The whole legislative goal of having increased public safety … all their policies are running against that, and they’re actually increasing the public safety risk rather than decreasing it.”

    Whitney has long advocated for product-level regulation rather than wholesale bans, suggesting age restrictions, testing requirements and proper labeling would be sufficient, “if it’s intoxicating.”

    “That’s all you need to do,” he said.

    Additionally, current regulatory approaches, he argued, are creating a false binary.

    “The dispensary model for marijuana is failed. It’s an abject failure because it’s limiting people’s access,” he said. “Not everybody wants to go in there.”

    Whitney also noted that declining commodity prices for corn, wheat, soybeans and other staple crops have driven farmers to seek higher-revenue alternatives. Hemp represents not only potential increased revenue per acre but also agricultural benefits – if the industry is actually allowed to develop.

    “Hemp is a great rotational crop because it helps with the soil, it restores certain aspects of the soil, and it takes impurities out of the soil,” Whitney explained. He added that using hemp in rotation can increase output for subsequent soybean crops “on a significant per bushel level.”

    Despite the challenges, Whitney still forecasts potential growth, projecting “a million acres in 2030, which is twice the size of it at its peak.”

    Many have attributed much of the regulatory confusion to federal inaction, particularly from the FDA, which has taken a hands-off approach and created much of the uncertainty. Whitney expressed hope that the upcoming farm bill might provide greater clarity, though he noted the legislation “has been pushed out a number of times.”

    The post Regulatory chaos threatens US hemp industry appeared first on Green Market Report.

  • Report: California regulators suspend cannabis lab’s business license for questionable test results

    Report: California regulators suspend cannabis lab’s business license for questionable test results

    California marijuana testing facility BelCosta Labs in Long Beach lost its business permit for allegedly inflating THC potency results for clients and other infractions, MJBizDaily reported Thursday, citing an April 10 letter from state regulators to the lab which said its permit was suspended “effective immediately.”

    The California Department of Cannabis Control also accused the lab of clearing marijuana products for sale that had failed contamination tests and were a potential threat to consumers.

    A spokesman for the lab, however, told MJBizDaily that the company believed it “was doing everything right” and obeying all state cannabis testing regulations.

    “We also don’t believe that we were anything close to a public safety or health concern,” BelCosta Vice President Nate Winokur told MJBizDaily.

    On Thursday, the DCC’s license database listed the lab’s permit as “suspended.” The license is set to expire April 30.

    It’s also not clear from the DCC letter if BelCosta has any immediate remedy to restart operations. CEO Myron Ronay indicated the lab may wind up suing the state if its permit is not restored.

    “If we cannot come to an agreement that salvages the business we have built over the last 8+ years we will be forced to resort to the court system,” Ronay wrote in an email to MJBizDaily.

    BelCosta executives also took to YouTube to publicly refute the DCC charges in the suspension letter and proclaimed that any issues were innocent mistakes, not nefarious rulebreaking. Winokur also suggested to MJBizDaily that his company may have been “singled out” by regulators for some reason.

    The post Report: California regulators suspend cannabis lab’s business license for questionable test results appeared first on Green Market Report.

  • Fluent posts $40M loss for 2024 despite New York entry, other expansion efforts

    Fluent posts $40M loss for 2024 despite New York entry, other expansion efforts

    Florida-based Fluent Corp. (CSE: FNT.U) (OTCQB: CNTMF) posted a $40.3 million net loss for the 2024 calendar year against $103.5 million in net revenues, the company reported on Thursday after U.S. markets closed.

    The annual loss was up 78% year-over-year from the $22.7 million net loss reported in 2023, which CEO Robert Beasley didn’t bother addressing in a press release.

    Rather, Beasley said the company is “positioning ourselves for continued success in the year ahead,” with the acquisition of RIV Capital in New York last year, followed by a rebranding from Cansortium to Fluent Corp., the launch of several new product lines and other expansion efforts that he said are already bearing fruit.

    Beasley also denied that the failure of recreational marijuana legalization at the ballot box last fall in Florida had a significant impact on the company’s business plans, but admitted the company’s been “somewhat impacted by broader industry dynamics.”

    “Many in the sector had prepared extensively for the amendment’s passage, and its delay has created market challenges, such as oversupply, heightened competition and increased product discounting,” Beasley said.

    For the fourth quarter, which ended on Dec.31, 2024, Fluent reported a year-over-year revenue downturn to $24.9 million from $25.5 million. For the full year, however, revenues were up 6.4% to $103.6 million from $97.3 million.

    In the final quarter of the year, Fluent also reported an impairment of intangible assets of $64.3 million, which it said was related to a license in Florida and “reduces the carrying value of the Company’s intangible assets on its consolidated statements of financial position to $37.6 million.”

    Fluent currently operates 42 dispensaries in Florida, New York, Pennsylvania and Texas, and said it expects to open at least three more in 2025. The company also expects to finish construction at a new cannabis cultivation facility in Tampa Bay by the end of the second quarter, which will add another 7,000 square feet of canopy to its production capacity.

    The company recently refinanced a $71 million loan from Chicago Atlantic that had been set to mature in May and inked a new $96.5 million credit line with the firm.

    At the end of December, Fluent had $61.4 million in total assets, including $40.1 million in cash, against $215.9 million in total liabilities.

    The post Fluent posts $40M loss for 2024 despite New York entry, other expansion efforts appeared first on Green Market Report.

  • STATES Act reintroduced in Congress with bipartisan support

    STATES Act reintroduced in Congress with bipartisan support

    A small bipartisan group of U.S. House of Representatives members on Thursday reintroduced the long-stalled STATES Act, a pro-marijuana bill that would both nullify the hated 280E tax provision for cannabis companies and also exempt states that have legalized marijuana from federal interference.

    The bill, this time called the STATES 2.0 Act, was introduced by U.S. Reps. Dave Joyce (R-OH), Dina Titus (D-NV) and Max Miller (R-OH). Joyce also introduced a separate bill co-sponsored by House Minority Leader Hakeem Jeffries (D-NY) dubbed the PREPARE Act, which is designed to pave the way for federal marijuana legalization.

    The first bill’s full name is the Strengthening the Tenth Amendment Through Entrusting States (STATES) 2.0 Act. If approved by both chambers and President Donald Trump, it would effectively remove states that have legalized marijuana from the jurisdiction of the federal Controlled Substances Act, reconciling legal tension between federal cannabis prohibition and state marijuana legality.

    The bill would also nullify the 280E provision of the federal tax code for licensed cannabis companies in states with legalized marijuana markets, thereby allowing the industry to claim standard business tax deductions and saving companies billions of dollars in taxes per year.

    Under the legislation, federal regulation of the national cannabis trade would fall to the Alcohol and Tobacco Tax and Trade Bureau and the Food and Drug Administration, meaning there would likely be a new federal regulatory framework for businesses that would apply to every state and U.S. territory that has legalized cannabis.

    “We can all agree that the current federal approach to cannabis policy is not working. As President Trump has acknowledged, the existing policy has caused unnecessary harm and squandered taxpayer dollars by diverting law enforcement resources from combatting violent crimes,” Joyce, the co-chair of the Congressional Cannabis Caucus, said in a press release. “The STATES 2.0 Act remedies this issue by bridging the gap between federal and state policy to create a more logical approach to cannabis regulation that allows each state to put the policies in place that work best for their communities.”

    Titus, the other co-chair of the Cannabis Caucus, said the STATES Act “ensures the federal government does not interfere with states or tribes that have chosen to legalize cannabis.”

    “It’s time for national policy to catch up with the states or at least get out of the way,” Titus said.

    The bill would also allow for interstate cannabis commerce, Shanita Penny, executive director of the Coalition for Cannabis Policy, Education and Regulation (CPEAR), said, and provide safe harbor for financial institutions, opening access to broader capital markets for marijuana companies.

    “We hit on all the typical business concerns” with the new STATES Act, Penny said, adding that if the bill was to become law it would make the SAFE Banking Act unnecessary.

    “This is that overarching federal framework that is going to ensure consistency across states for not only businesses … it’s an exciting bill for everybody involved,” Penny said.

    That said, the measure’s chances of getting through both chambers of Congress and all the way to the president’s desk are unclear. In past years, most pro-cannabis bills have died in the Senate, even if they made it through the House of Representatives. Penny also noted that so far there’s no Senate version of the STATES Act this year.

    “We don’t have a Senate companion bill. So before we can even talk about giving them an opportunity to move forward with this … we still have some work to do there,” she said. “While we certainly haven’t had any indications from Trump that there’s going to be action on this, what we have right now is an opportunity to reengage members… to make sure that when the administration gives us the green light, that we have a bill we can get passed and get onto his desk.”

    The post STATES Act reintroduced in Congress with bipartisan support appeared first on Green Market Report.

  • 4Front Ventures delays annual filings, can’t pay auditors

    4Front Ventures delays annual filings, can’t pay auditors

    4Front Ventures (CSE: FFNT) (OTCQB: FFNTF) said Wednesday it can’t meet its April 30 regulatory deadline to file its annual financial report because it can’t pay its auditors.

    The Phoenix-based company also applied for a management cease trade order that would temporarily restrict company leaders from trading its securities while it tries to fix its money problems.

    The delay comes as the company works to “resolve the issue and expects to be able to file the necessary reports upon completion of securing additional financing, restructuring its liabilities and continuing discussions with one of the company’s lessors,” according to a news release. Management stated that it expects to file within 60 days of restarting its audit.

    The delay follows a tough stretch for 4Front, which lost $6.4 million in the third quarter while watching its revenue slide. Third-quarter revenue dropped to $15.2 million, down from $20.1 million a year earlier and lower than the $18.7 million from the previous quarter.

    The company blamed “softness in our retail channel stemming from heightened competition” in both Illinois and Massachusetts markets for the revenue dip.

    Still, CEO Andrew Thut previously tried to sound positive, saying the company was making progress on scaling production in Illinois, growing wholesale in Massachusetts and seeing better results in Washington.

    “Despite the uncertainties surrounding federal cannabis reform, we’re optimistic, especially given signs that we may have unexpected advocates in the incoming administration,” Thut said at the time. “We’re confident entering Q4 and are ready to return to growth and sustainable positive cash flows from operations.”

    4Front also said at the time that it retained Canaccord Genuity to help with an internal reorganization, particularly regarding its financial position. The company also took out an $850,000 loan to finance ongoing operations.

    The company asked for relief under Canadian National Policy 12-203, which would block management from trading company securities until it files its financials. The Ontario Securities Commission hasn’t ruled on this request yet.

    If rejected, the commission might instead impose a broader order affecting all company securities.

    While the filings remain outstanding, 4Front promised to provide biweekly status updates and confirmed that insiders can’t trade company stock until the annual filings are submitted.

    The company has been pushing growth initiatives despite its financial crunch. During the third quarter, it continued building a massive 250,000-square-foot cultivation facility in Matteson, Illinois, planning to expand from 24,000 to 34,800 square feet of growing space. Its Massachusetts wholesale business showed some promise with a 56% increase in revenue to nearly $2 million for the quarter.

    As of September 2024, 4Front had $278 million in assets, with just $1.2 million in cash, against $326.5 million in liabilities, including nearly $69 million in debt.

    The company said there are no bankruptcy proceedings underway and “no material business developments” since filing its last quarterly report in December beyond what its already disclosed.

    The post 4Front Ventures delays annual filings, can’t pay auditors appeared first on Green Market Report.

  • Safe Harbor Financial, FundCanna team up to tackle cannabis banking headaches

    Safe Harbor Financial, FundCanna team up to tackle cannabis banking headaches

    Safe Harbor Financial (Nasdaq: SHFS) and FundCanna are joining forces to help cannabis businesses break through persistent banking and money barriers, the companies announced Thursday.

    The new referral deal between Safe Harbor and fellow lender FundCanna creates a one-stop solution for marijuana operators who’ve been largely shut out of traditional banking services.

    The setup: Safe Harbor will send clients to FundCanna when they need loans or equipment financing, while FundCanna will direct its borrowers to Safe Harbor’s banking services. All loan money will flow through Safe Harbor-managed accounts, keeping everything above board, according to the news release.

    “This partnership delivers a practical, scalable solution that puts the financial needs of cannabis operators first,” said Terry Mendez, Safe Harbor’s new CEO, who’s trying to breathe new life into the company after a rough financial stretch.

    Safe Harbor recently posted mixed results for 2024 – its lending business is booming – up 123% for the year – but the company still recorded a hefty $48.3 million loss. Still, Mendez, who took over earlier this year after Sundie Seefried’s retirement, has big plans to overhaul the company.

    In March, he told shareholders he wants to transform Safe Harbor from just a cannabis banking operation into a comprehensive business services hub – including expanded lending, which the FundCanna deal supports.

    FundCanna’s founder Adam Stettner says the partnership “brings together two trusted platforms dedicated to solving persistent financial barriers in cannabis.” His team has pumped $20 billion into various underserved businesses over two decades.

    The collaboration comes as cannabis companies continue to struggle with cash constraints while traditional banks keep them at arm’s length due to federal prohibition. For Safe Harbor, which has already processed $25 billion in cannabis transactions since its 2015 founding, it says, the deal represents a key piece of Mendez’s vision to serve not just cannabis but eventually other “debanked” industries like crypto and gaming.

    The post Safe Harbor Financial, FundCanna team up to tackle cannabis banking headaches appeared first on Green Market Report.

  • Florida’s marijuana patient base continues to grow as lawmakers target hemp industry

    Florida’s marijuana patient base continues to grow as lawmakers target hemp industry

    Florida’s medical marijuana registry continues to grow, adding roughly 14,000 patients in early 2025. That trend could continue as lawmakers target a key competitor for the industry, proposing tough new hemp rules that could reshape the state’s cannabis scene.

    Patient numbers rose steadily from 895,000 in January to 909,000 by April, according to the Florida Office of Medical Marijuana Use. Meanwhile, Florida senators unanimously backed legislation to restrict hemp-derived THC products, resembling a bill Gov. Ron DeSantis vetoed last year after hemp industry pressure, with some caveats.

    “We have retailers in the state of Florida that are selling products that are intoxicating,” the Florida Phoenix reported Republican Sen. Colleen Burton, the bill’s sponsor, as saying. “They are selling products that are putting adults and children in the hospital. And, sadly, they are selling products that are causing the deaths of Floridians.”

    Senate Bill 438 would ban Delta-8 products outright and limit Delta-9 hemp items to 5 milligrams per serving, according to the legislative text. THC-infused beverages would face the same cap and would only be allowed to be sold by businesses with liquor licenses, similar to legislation creeping its way through statehouses across the country.

    Recent testing of products from smoke shops across Florida found concerning potency issues: 50 of 53 hemp flower samples exceeded the federal 0.3% THC limit, making them essentially unregulated marijuana products, according to testimony during legislative hearings.

    “These are very intoxicating products,” Republican Sen. Gayle Harrell, who represent southeast Florida, said. “They’re addicting products at the end of the day. And people need to know that. … We need to make sure that people know what they’re buying. And we have seen so many fly-by-night places selling hemp – ‘safe hemp’ – and the THC levels are higher than the medical marijuana that you can get in a dispensary.”

    In some ways, hemp products have become a legitimate competitive threat for established cannabis companies. According to Viridian Capital Advisors, “It’s not exactly a closely held secret that hemp intoxicants, along with illicit THC vendors, have hit the THC industry right where it hurts.”

    Viridian’s report noted that analysts project “flat revenues for the top 12 MSOs for 2025″ while the hemp industry continues to grow due to price and convenience advantages. Consumers often “don’t care about seed-to-sale tracking and a (certificate of analysis) on every bottle. They will gladly trade that for the ability to purchase at their gas station or, better yet, online through the mail, especially if it costs less,” the Viridian report stated.

    That shift has pushed even major players like Curaleaf to hedge their bets. The international cannabis giant will open a hemp dispensary in Florida that will offer both its own Select brand and third-party hemp-derived THC beverages and edibles.

    “The move makes complete sense, going along with Curaleaf’s 2024 launch of the Hemp Company,” the Viridian analysis noted.

    But the political animosity around hemp regulation in the state remain complex. After DeSantis vetoed similar restrictions last year, a slew of hemp business owners donated to DeSantis’ efforts to defeat Amendment 3, which would have legalized recreational cannabis for adults aged 21 and above.

    Jacksonville Democratic Sen. Tracie Davis, who co-sponsored the bill, acknowledged during floor debate that the legislation wasn’t much different from last year’s vetoed version.

    If passed by the House and signed into law, the Department of Agriculture would handle enforcement with $2 million allocated to law enforcement for testing equipment.

    The bill also poses deeper questions about cannabis regulation frameworks. As Viridian framed it: “If cannabis is medicine, then perhaps it really should be heavily regulated by the FDA and heavily tested as well. But if cannabis is more analogous to wine or spirits, only less dangerous, then a whole other set of policy structures is appropriate.”

    The report points out: “You can easily walk into a liquor store and purchase enough Jack Daniels to kill five people, but nobody will question your right to make that purchase. Why potency or quantity limits for cannabis, which most people agree is less dangerous?”

    !function(){“use strict”;window.addEventListener(“message”,(function(a){if(void 0!==a.data[“datawrapper-height”]){var e=document.querySelectorAll(“iframe”);for(var t in a.data[“datawrapper-height”])for(var r,i=0;r=e[i];i++)if(r.contentWindow===a.source){var d=a.data[“datawrapper-height”][t]+”px”;r.style.height=d}}}))}();

    The post Florida’s marijuana patient base continues to grow as lawmakers target hemp industry appeared first on Green Market Report.